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Background: Diabetes is closely linked with coronary artery disease, either by means of direct effects of
hyperglycemia, or indirectly by its frequent association with dyslipidemia. Any treatment for diabetes that has
beyond the capacity of reduce glycated hemoglobin, the propensity to improve lipid profile and reduce weight will
bring many benefits to patients.
Method: We compare the effects of vildagliptin with the gliclazide on lipid profile before and after a standardized
meal test, on glycemic control and oxidative stress in diabetic patients using metformin without adequate glycemic
control. This is a prospective study of 16 weeks with diabetic patients using metformin without adequate glycemic
control. Patients were randomized to receive gliclazide 30–120 mg/day or vildagliptin 100 mg/day.
Results: 36 patients were randomized, with no loss of follow up. Regarding the lipid profile the difference observed
at the end of the study was a higher HDL level in the vildagliptin group compared with gliclazide fasting (62.3 vs.
51.3 mg/dL, p = 0.021) and postprandial (62.9 vs. 51.1 mg/dL, p = 0.015). We also observed a variation of negative
weight (decrease the end compared to the beginning) of the vildagliptin and a positive (increase) in the gliclazide
(−0.3 vs. +1.4 Kg, p = 0.048). The decrease in A1c was lower in the vildagliptin group compared to gliclazide (−1.7
vs.−2.3 %, P = 0.031), however there was no difference in the number of patients reaching target glycated
hemoglobin <7 % (50 vs. 61.1 %, p = 0.738). Only the group of vildagliptin presented at the end of the study
compared to the beginning, decreased insulin values (599.6 vs.705, 59 pg/ml, p = 0.021), glucagon
(46.6 vs.65, 2 pg/ml, p = 0.004) and the marker of oxidative stress TBARS (8.0 vs. 9.0 nmol MDA/ml, p = 0.035).
Conclusion: Vildagliptin showed some advantages in addition to metformin in relation to addition of gliclazide.
Patients treated with vildagliptin had a higher HDL at the end of the study, less variance in weight, reduced insulin
and glucagon as well as reduction of oxidative stress.* Correspondence: marcelo_hissa@yahoo.com.br
1Department of Surgery, Postgraduate Program, UFC, Fortaleza, Ceara, Brazil
Full list of author information is available at the end of the article
© 2015 Hissa et al. This is an Open Access article distributed under the terms of the Creative Commons Attribution
License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction
in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Hissa et al. Diabetology & Metabolic Syndrome  (2015) 7:62 Page 2 of 7Introduction
Diabetes is a devastating disease that currently affects
more than a billion people worldwide [1, 2]. Patients
with diabetes have a significantly increased risk of mor-
bidity and mortality associated with cardiovascular dis-
ease and stroke, causing 75 % of all deaths [3–5].
Furthermore, type 2 diabetes mellitus (T2DM) is usually
associated with other factors like hypertension, dyslipid-
emia, obesity and accelerated atherosclerosis risk that
contributes to an even higher morbidity and cardiovas-
cular mortality [6].
Free radicals are formed disproportionately in diabetes
by glucose oxidation, nonenzymatic glycation of pro-
teins, and the subsequent oxidative degradation of gly-
cated proteins. Abnormally high levels of free radicals
and simultaneous decline of antioxidant defense mecha-
nisms can lead to damage of cellular organelles and en-
zymes, increased lipid peroxidation, and development of
insulin resistance. Conversely insulin resistance is associ-
ated with atherogenic dyslipidemia, with the postpran-
dial hyperlipidemia playing an important role in this
state [7, 8]. It is well known that impaired clearance
from the circulation of intestinally-derived lipoprotein
particles and their lipid content contributes to postpran-
dial hyperlipidemia in those with insulin resistance and
T2DM [9].
Gliclazide is a second generation sulphonylurea (SU)
most prescribed in many countries. It has advantage
over others SUs because of its selectivity. Individual SUs
express a different selectivity for pancreatic and myocar-
dial SU receptors; gliclazide seems the most selective
with respect to pancreatic receptor stimulation, and thus
showing a cardiovascular benefits over others SUs [10].
Vildagliptin is a compost of the DPP-4 inhibitor drug
class. It is a highly-selective substrate for the DPP-4
catalytic site with a slow reaction rate, which blocks the
usually rapid degradation of GLP-1 and glucose-
dependent insulinotropic peptide (GIP) [11, 12]. Vilda-
gliptin increases plasma level of GLP-1 and GIP, which
improves the sensitivity of the β- and α-cell to glucose;
there are also extra-pancreatic effects which contribute
to improved insulin sensitivity and attenuate weight
gain. In clinical studies, vildagliptin has been shown to
reduce HbA1c, fasting plasma glucose (FPG) & post-
prandial plasma glucose levels. Furthermore decreased
postprandial glycemic excursion might reduce the oxida-
tive stress markers and improve postprandial hyperlipid-
emia [13].
Results from clinical studies to date indicating that
dipeptydyl peptidase-4 (DPP-4) inhibitors reduce total
cholesterol are inconsistent. Based on these evidence,
this research was designed to evaluate the effect of vilda-
gliptin on the impact of DDP-4 inhibition on lipoprotein
metabolism by examining the effects of vildagliptin onpostprandial lipid levels and oxidative stress. We hy-
pothesized that in T2DM, treatment with vildagliptin
would improve lipoprotein levels and oxidative stress
more pronounced than treatment with gliclazide.
Subjects and methods
Study design
This is a 16-week open label randomized prospective
study conducted at the Diabetes Research Center/De-
partment of Internal Medicine, Federal University of
Ceara, Brazil.
The study protocol was approved by the local Ethical
Committee (Comite de etica em pesquisa/ Hospital uni-
versitario Walter Cantidio) and all eligible candidates
had to provide signed informed consent before enrolling
in the study.
Participants
We enrolled 36 patients with type 2 diabetes who had
been inadequately treated with metformin for at least
3 months (≥1,000 mg/day) expressed as HbA1c > 7,5 %.
Eligibility criteria included men or women 18–70 years of
age who were on metformin treatment for ≥3 months on
stable dose (≥1000 mg/daily) and body mass index be-
tween ≥ 22 and ≤ 40 kg/m2. The exclusion criterias were
following: (1) pregnant or nursing women; (2) use of any
anti-diabetic treatment within 3 months prior to visit 1
other than metformin; (3) chronic (>7 consecutive days)
oral, parenteral or intra-articular corticosteroid treatment
within 8 weeks prior to Visit 1; (4) history or evidence of
major hepatopathy (aspartate aminotransferase or alanine
aminotransferase activities > 2.5 times the upper limit of
normal); (5) ischemic heart disease or cerebrovascular
disease; (6) creatinine level > 0.133 mmol/L; (7) major
diabetes complications (chronic renal insufficiency,
proliferative retinopathy and stroke); (7) extreme
dyslipidemia, such as familial hypercholesterolaemia;
(8) use of antilipemic drug; (9) and a recent history of
alcohol or drug abuse.
Treatment protocol
The study consisted of a 2-week screening period and a
16-week treatment period with either vildagliptin or gli-
clazide plus metformin, followed by 4 week on follow
up. At the initial interview, height, body weight, vital
signs and physical examination were performed. Fasting
blood samples were performed to assure the inclusion
and exclusion criterias (A1c, fast glucose, hepatic func-
tion test, serum blood urea nitrogen and creatinine and
hematology). At visit 1 (2 weeks later) selected patients
were randomly assigned to either vildagliptin or glicla-
zide group. Participants assigned to vildagliptin group
were instructed to take one capsule (50 mg) before their
morning meal and before dinner. Participants assigned
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gliclazide before the morning meal. It was allowed to ti-
trate gliclazide to a maximum of 120 mg/daily. Compli-
ance was assessed by pill counting. Blood was also
collected at visit 1 (week zero) for the assessment of,
A1c, fast glucose, lipid profile (total cholesterol, trigly-
ceride, HDL cholesterol, oxidative stress markers [react-
ive substances to thiobarbituric acid (TBARS), total
antioxidant status (TAOS)]; Insulin, C- peptide, gluca-
gon, GLP-1 and GIP. All laboratory tests were repeated
in visit 5 (week 16) (Fig. 1).
Meal test
Before randomization (week 0) and at week 16 after
randomization, a standardized meal test (ensure plus®)
was given. It consisted of a milkshake containing 13 g
protein (16.7 %), 40 g carbohydrate (53.8 %) and 13 g
lipid (29.5 %) per 300 Kcal. The patients thereby
fasted overnight and an intravenous catheter was
inserted into a forearm vein for blood sampling.
Study drug was administered 30 min before consump-
tion of a standardized breakfast meal. The meal was
consumed within 5 min, and blood samples were
drawn before the meal (fasting state) and 3 h after
the meal (postprandial state) for the assessment of
lipid profile.
Assays and methods of dosage
Plasma glucose was assayed by glucose-oxidase
method (Dimension RxL Max Integrated Chemistry
System – Siemens AG, Erlangen, Germany); Patients
were also instructed to monitor their capillary blood
glucose by using a blood glucose monitor (Accu-Chek
Performa – Roche Diagnostica Brasil LTDA, São
Paulo, SP, Brazil). This was done every 3 to 5 days
before each visit (visit 2, 3 and 4), seven times a day
(before and 2 h after breakfast, lunch, dinner, and be-
fore supper).
Glycated hemoglobin (A1c) was determined by High-
performance liquid chromatography. Total cholesterol
(TC), triglycerides (TG), HDL-cholesterol (HDL), bloodFig. 1 Study designurea nitrogen (BUN), creatinine concentrations and hep-
atic function tests were determined using enzymatic ana-
lysis (Hitachi Modular P800 Chemistry Analyzer –
Roche Diagnostics, Indianapolis, IN, USA). Thiobarbitu-
ric Acid Reactive Substances (TBARS) and antioxidant
state (TAOS) were measured with the QuantiChromTM
Antioxidant Assay Kit (DTAC-100) (BioAssay Systems,
Hayward, CA, USA). Insulin, Glucagon, C-Peptide, glu-
cagon like peptide-1 (GLP-1) and gastric inhibitory poly-
peptide (GIP) were measured with the Human
Metabolic Hormone Magnetic Bead Panel 96 Well Plate
Assay (EMD Millipore Corp., St. Charles, MO, USA).
Statistical analysis
In order to characterize the population of each group
and compare some characteristics, descriptive analysis of
frequency measurements was performed when the vari-
able was qualitative; mean and standard variations when
the variable was quantitative. In the comparison of
qualitative independent variables the chi-square Pearson
test was used. The quantitative variables were tested for
normality by the Shapiro-Wilk test. For independent
variables, in the presence of normality, the homogeneity
of variance of the groups was evaluated using the
Levene’s test. Given the homogeneity, the difference be-
tween groups was tested by applying ANOVA. In case of
failure to evidence the homogeneity by Levene’s test, the
differences between the independent variables were cal-
culated using the Welch test. The distinction between
quantitative variables without normality was verified
using the Mann–Whitney test. In the case of paired vari-
ables that were proved normality, inequalities between
groups were analyzed by paired t test. If there was nor-
mality, the test used to compare this type of variable was
the Wilcoxon. The exact significance was evaluated by
two-tailed test.
Results
The study enrolled 36 patients, 18 randomized to Gliclazide
group (mean daily dose 86.8 ± 28.1 mg) and 18 for the
Vildagliptin. There was no loss of follow up of any of the
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were observed between the two groups at baseline
(Table 1).
There were no differences between the two groups
at baseline for biochemical tests. This is also true for
lipid profile before and after a standardized meal test
concerning total cholesterol, HDL-cholesterol and tri-
glycerides (Table 2).
After the 16 week study, in the stage of post-treatment,
total cholesterol and triglyceride levels in fasting and
postprandial remained without differences [(p = 0.904
and p = 0.899) and (p = 0.635 and p = 0.342), respect-
ively]. However we observed an increase statistically
significant in HDL cholesterol levels in fasting and
postprandial (p = 0.021 and p = 0.015, respectively) in
the Vildagliptin group (Table 2).
Regarding the weight, there was a difference be-
tween the groups before pretreatment. This was
higher in the gliclazide compared to vildagliptin group
(82.0 ± 14.6 kg and 71.4 ± 8.0 kg, respectively, p = 0.012)
and this difference persisted after treatment (83.4 ± 14.8
and 71.0 ± 8.1 kg, respectively, p = 0.012). It is important
to note that while in the gliclazide group, the variation of
weight (post-treatment weight less pre-treatment
weight) was positive (1.4 ± 3.0 kg) in the vildagliptin
group it was negative (−0.3 ± 2.0 kg), with statistical
significance (p = 0.048).
No differences were observed between the two
groups in fasting and postprandial glucose levels in
pretreatment (p = 0.475 and p = 0.896, respectively) as
well as post-treatment (p = 0.825 and p = 0.847). A1c
also showed no differences between groups in pre
and post-treatment (p = 0.109 and p = 0.800 respect-
ively) and in the number of patients reaching target
glycated hemoglobin <7 % (50 vs. 61.1 % [p = 0.738],
vildagliptin vs. gliclazide respectively).
Patients who used gliclazide showed no significant
changes from pre to post-treatment regarding to insu-
lin (p = 0.160), glucagon (p = 0.921), GLP-1 (p = 0.218),
GIP (p = 0.201) and C-peptide levels (p = 0.193).
TBAR and TAOS also showed no significant changes
(p = 0.262 and p = 0.179, respectively) (Table 3).Table 1 Patient demographics and baseline characteristics (random
Demographic Gliclazide (n = 18)
Age (years) 55.4 ± 11.3
Sex (number of men) 6
BMI (kg/m2) 30.68 ± 4.3
Duration of diabetes (years) 4.4 ± 2.6
Duration of previous metformin treatment (months) All patients were on
Metformin daily dose (mg) 1457 ± 373
Gliclazide daily dose (mg) 86,80 ± 28,10
Data are means ± SD unless otherwise indicatedRegarding the patients who used Vildagliptin, there
was a significant decrease in insulin (p = 0.021), and glu-
cagon levels (p = 0.004). There was significant increase
in GLP-1 level (p = 0.026). There was a significant de-
crease in oxidative stress marker TBARS (p = 0.035).
No difference was observed in TAOS (p = 0.417), GIP
(p = 0.405) and C-peptide levels (p = 0.059) (Table 3).
Discussion
For a long time, the association between cardiovascu-
lar disease and metabolic abnormalities during fasting
state has been largely studied. However, more re-
cently, metabolic abnormalities in postprandrial state
have being recognized as important contributors to
cardiovascular disease in T2DM and in other condi-
tions associated with insulin resistance. Postprandial
hyperglycemia has been reported as having a greater
impact in cardiovascular disease and mortality than
fasting hyperglycemia [14]. Others factors, like post-
prandial hyperlipidemia, have been also addressed as
contributors to cardiovascular disease as assessed by
several studies [15–21]. Clinical studies in T2DM
with DPP-4 inhibitors provide evidences that incretin-
based therapies improve fasting and postprandial gly-
cemia and somewhat also dyslipidemia [22–25].
Our results confirm the benefits of vildagliptin, a DPP-4
inhibitor, in the HDL level of diabetic patients. Previous
studies initially performed in rats [26] and subsequently in
humans, demonstrated an increase in HDL in patients re-
ceiving vildagliptin [27]. This effect was observed at a dose
of 50 mg/day, but it was greater when using 100 mg/day.
This benefit occurs in both treatment-naïve patients, as in
those that were already in use of metformin and had vilda-
gliptin added [27–29]. In our study, at baseline there was
no difference in HDL between the vildagliptin and glicla-
zida groups. After 16 weeks of follow up the patients in
vildagliptin group showed better HDL in fasting and post-
prandial than the patients in gliclazide group. However,
differently from literature data, we did not observed in
our sample any differences in other lipid particles [27, 29].
The evaluation of patients’ weight between groups was
hampered by a difference already in pre-treatmentized population)





metformin treatment for ≥3 months on stable dose (≥1000 mg/daily)
1584 ± 528
-
Table 2 Comparision of laboratory tests and weight between the two groups before and after treatment
Pretreatment Post treatment
Week 0 Week 16
Parametes Gliclazide Vildagliptin P Gliclazide Vildagliptin P
Fasting TC (mg/dL) 195.2 ± 26.9 190.1 ± 35.8 0.636 194.0 ± 32.2 192.6 ± 36.4 0.904
Postprandial TC (mg/dL) 193.1 ± 25.9 186.8 ± 34.8 0.544 191.3 ± 32.9 192.8 ± 37.2 0.899
Fasting HDL (mg/dL) 51.1 ± 10.0 60.0 ± 18.9 0.086 51.3 ± 10.4 62.3 ± 15.6 0.021
Postprandial HDL (mg/dL) 50.2 ± 9.3 59.3 ± 17.9 0.150 51.1 ± 10.8 62.9 ± 16.0 0.015
Fasting Triglycerides (mg/dL) 177.3 ± 87.3 197.1 ± 116.0 0.567 205.1 ± 100.3 190.7 ± 106.2 0.635
Postprandial Triglycerides (mg/dL) 207.9 ± 89.3 218,4 ± 110.0 0.849 221.8 ± 90.1 197.4 ± 86.1 0.342
Fasting glucose (mg/dL) 179 ± 57.9 168.7 ± 31.3 0.475 131.7 ± 30.5 132.9 ± 24.8 0.896
Post prandial glucose (mg/dL) 242.83 ± 71.7 241.4 ± 69.5 0.825 191.2 ± 54.8 194.5 ± 47.4 0.847
A1c (%) 9.2 ± 1.2 8.6 ± 0.9 0.109 6.9 ± 1.1 6.9 ± 0.8 0.800
Weight 82.0 ± 14.6 71.4 ± 8.0 0.012 83.4 ± 14.8 71.0 ± 8.1 0.005
Weight Change (kg) - - - +1.4 ± 3.0 −0.3 ± 2.0 0.048
Data are means ± SD. TC total cholesterol, HDL high dense lipoprotein
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Our data is agreement to the literature [30, 31]. We
observed a positive variance (weight gain) in the gli-
clazide group and a small negative balance (weight
loss) in vildagliptin group [32].
Assessing hormonal status of patients within each
group before and after treatment, we were able to
realize others benefits of vildagliptin. Besides the ex-
pected effects in increasing of GLP-1, we also ob-
served significant changes in insulin and glucagon
levels in Vildagliptin group.
The main mechanism of action of sulfonylureas through
the ATP-sensitive potassium channels leads to increased
insulin secretion, therefore were expected higher insulin
levels following the introduction of gliclazide. The litera-
ture demonstrates that DPP4 inhibitors also lead to in-
creased insulin due to improved beta-cell function, but we
observed the opposite effect. Decreased insulin levels may
be partially inferred from the reduction of insulin resist-
ance with improved glycemic control [33–35].Table 3 Intragroups comparation of laboratory tests before (week 0
Parameters Gliclazide
Week 0 Week 16
Insulin (pg/mL) 716 ± 316.7 819.7 ± 391.9
Glucagon (pg/mL) 79.1 ± 43.1 77.7 ± 40.0
A1c (%) 9.2 ± 1.2 6.9 ± 1.1
C-peptide (pg/mL) 1882.0 ± 690.1 2092.8 ± 956.2
GLP-1 pg/mL) 38.3 ± 25.3 45.5 ± 21.1
GIP (pg/mL) 39.1 ± 15.2 45.6 ± 39.0
TBAR (nmolMDA/mL) 8.9 ± 1.4 8.47 ± 0.9
TAOS 215.9 ± 34.5 264.3 ± 34.0
Data are means ± SD. GLP-1, Glucagon like peptide 1; GIP Gastric inhibitory polypepThe DPP4 inhibition by vildagliptin results in less deg-
radation of GLP-1 leading to the expected effect in im-
proving glycemic control. The decrease in glucagon
levels, as observed only in vildagliptin group, is one of
the important consequences caused by the increase of
GLP-1. Such reduction diminishes the release of glucose
mainly in the postprandial period. The intestinal hor-
mone GIP also increased due to the inhibition of DPP4,
however, in our sample this increase was insignificant.
There was a decrease in TBARS in the group treated
with vildagliptin, suggesting an additional benefit in the
oxidative stress. This data is in accordance with litera-
ture regarding the effects of vildagliptin in oxidative
stress [36, 37].
In conclusion, our study of 16 weeks with 36 T2DM
showed some advantages in added vildagliptin instead of
gliclazide to metformin in the treatment of uncontrolled
hyperglycemia. Although both drugs effectively reduce
A1c, vildagliptin has additional effects besides glycemic
control. Patients treated with vildagliptin had a higher) and after treatment (week 16)
Vildagliptin
P Week 0 Week 16 P
0.160 705.59 ± 468.8 599.6 ± 417.7 0.021
0.921 65.2 ± 36.1 46.6 ± 30.8 0.004
0.000 8.7 ± 0.9 6.9 ± 0.9 0.000
0.193 1627.2 ± 585.6 1622.6 ± 609.6 0.059
0.218 44.7 ± 38.7 83.8 ± 74,5 0.026
0.201 38.9 ± 25.7 44.7 ± 34.8 0.405
0.262 9.0 ± 1.6 8.0 ± 0.7 0.035
0.179 257.5 ± 61.3 205.3 ± 28.2 0.417
tide, TBARS Thiobarbituric Acid reactive substances, TAOS antioxidant state
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dial. TBARS, a marker of oxidative stress, was reduced
with vildagliptin treatment, suggesting some ability of
this drug in modulating oxidative stress. Finally vilda-
gliptin seems to reduce insulin resistance demonstrated
by both reduction in serum levels of insulin and gluca-
gon. To confirm those datas others studies with a longer
period of treatment and a greater number of patient are
necessary. It is also should be prudent to have studies
with others oxidative stress parameters.
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